Sign In
Buy ENLV
$0.611
-0.0122 (-1.96%)
At Close: Jun 23, 2026
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
08:30am, Tuesday, 03'rd Dec 2024
ABOUT ENLIVEX Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
10:15am, Tuesday, 26'th Nov 2024
NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite inve
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
08:00am, Thursday, 14'th Nov 2024
Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Thursday, 31'st Oct 2024
Enlivex Therapeutics (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
08:00am, Wednesday, 30'th Oct 2024
Nes-Ziona, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
New Strong Buy Stocks for October 23rd
08:20am, Wednesday, 23'rd Oct 2024
RENT, DSGR, PTON, ENLV and GTEC have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2024.
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
01:00pm, Wednesday, 11'th Sep 2024
Enlivex Therapeutics (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 30'th Aug 2024
ORLANDO, FL / ACCESSWIRE / August 30, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (Nasdaq:GP) and Enlivex Therapeutics Ltd. (Nasdaq:ENLV) on the RedChip Small Stock
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 19'th Jul 2024
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money�
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
08:00am, Monday, 17'th Jun 2024
Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of AllocetraTM into the knee as a “last resort” T
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
04:15pm, Wednesday, 29'th May 2024
Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the cl
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
08:12am, Tuesday, 28'th May 2024
Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that i
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
02:05pm, Monday, 15'th Apr 2024
Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
